4'-cyanomethyl-2-(isoquinolin-3-yl)acetanilide | 1160620-11-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 4'-cyanomethyl-2-(isoquinolin-3-yl)acetanilide
• 英文别名: N-[4-(cyanomethyl)phenyl]-2-isoquinolin-3-ylacetamide
• CAS: 1160620-11-0
• 化学式: C₁₉H₁₅N₃O
• 分子量: 301.348
• InChiKey: XCCSVCQPLLDJDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  65.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4'-cyanomethyl-2-(isoquinolin-3-yl)acetanilide 在 ammonium hydroxide 、 氢气 、 镍 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  Discovery of novel acetanilide derivatives as potent and selective β3-adrenergic receptor agonists

  摘要：

  In the search for potent and selective human beta 3-adrenergic receptor (AR) agonists as potential drugs for the treatment of obesity and noninsulin-dependent (type II) diabetes a novel series of acetanilide-based analogues were prepared and their biological activities were evaluated at the human beta 3-, beta 2-, and beta 1-ARs. Among these compounds, 2-pyridylacetanilide (2f), pyrimidin-2-ylacetanilide (2u), and pyrazin-2-ylacetanilide (2v) derivatives exhibited potent agonistic activity at the beta 3-AR with functional selectivity over the beta 1- and beta 2-ARs. In particular, compound 2u was found to be the most potent and selective beta 3-AR agonist with an EC(50) value of 0.11 mu M and no agonistic activity for either the beta 1 - or beta 2-AR. In addition, 2f, 2u, and 2v showed significant hypoglycemic activity in a rodent diabetic model. (C) 2009 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2009.01.022
• 作为产物：
  描述：

  对氨基苯乙腈 、 ethyl 2-(isoquinolin-3-yl)acetate 以 5,5-dimethyl-1,3-cyclohexadiene 为溶剂， 反应 19.0h， 以67%的产率得到4'-cyanomethyl-2-(isoquinolin-3-yl)acetanilide
  参考文献：
  名称：

  Discovery of novel acetanilide derivatives as potent and selective β3-adrenergic receptor agonists

  摘要：

  In the search for potent and selective human beta 3-adrenergic receptor (AR) agonists as potential drugs for the treatment of obesity and noninsulin-dependent (type II) diabetes a novel series of acetanilide-based analogues were prepared and their biological activities were evaluated at the human beta 3-, beta 2-, and beta 1-ARs. Among these compounds, 2-pyridylacetanilide (2f), pyrimidin-2-ylacetanilide (2u), and pyrazin-2-ylacetanilide (2v) derivatives exhibited potent agonistic activity at the beta 3-AR with functional selectivity over the beta 1- and beta 2-ARs. In particular, compound 2u was found to be the most potent and selective beta 3-AR agonist with an EC(50) value of 0.11 mu M and no agonistic activity for either the beta 1 - or beta 2-AR. In addition, 2f, 2u, and 2v showed significant hypoglycemic activity in a rodent diabetic model. (C) 2009 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2009.01.022

文献信息

• Discovery of novel acetanilide derivatives as potent and selective β3-adrenergic receptor agonists
  作者：Tatsuya Maruyama、Kenichi Onda、Masahiko Hayakawa、Tetsuo Matsui、Toshiyuki Takasu、Mitsuaki Ohta

  DOI：10.1016/j.ejmech.2009.01.022

  日期：2009.6

  In the search for potent and selective human beta 3-adrenergic receptor (AR) agonists as potential drugs for the treatment of obesity and noninsulin-dependent (type II) diabetes a novel series of acetanilide-based analogues were prepared and their biological activities were evaluated at the human beta 3-, beta 2-, and beta 1-ARs. Among these compounds, 2-pyridylacetanilide (2f), pyrimidin-2-ylacetanilide (2u), and pyrazin-2-ylacetanilide (2v) derivatives exhibited potent agonistic activity at the beta 3-AR with functional selectivity over the beta 1- and beta 2-ARs. In particular, compound 2u was found to be the most potent and selective beta 3-AR agonist with an EC(50) value of 0.11 mu M and no agonistic activity for either the beta 1 - or beta 2-AR. In addition, 2f, 2u, and 2v showed significant hypoglycemic activity in a rodent diabetic model. (C) 2009 Elsevier Masson SAS. All rights reserved.